Immuno-oncology (Hu)MAbs

OCR Number: 
OCR 6325
  • Neutralizing antibodies to OCR6325 are potential immune therapeutic agents to treat cancers that overexpress a novel soluble target expressed in epithelia (left figure).
  • CDRs are transferable for humanization.
  • In vivo small animal studies show that neutralization of the soluble protein target significantly reduces tumor burden in established tumors (both figures).
  • OCR6325 is a promising immunotherapeutic target for treating epithelial cancers.
  • Antibodies are to conserved epitope in human/mouse.
Licensing Contact: